Presentation on theme: "Patients' and their doctors’ preferences for adjuvant sorafenib after resection of intermediate to high risk RCC: what makes it worthwhile? Introduction."— Presentation transcript:
Patients' and their doctors’ preferences for adjuvant sorafenib after resection of intermediate to high risk RCC: what makes it worthwhile? Introduction The PAS in SORCE study is a longitudinal, observational study nested within the international SORCE Trial. Participants are all Australian patients (with sufficient English) and their doctors (medical oncologists & urologists). A number of UK patients and their doctors have also participated. Conclusions Patients judged small to moderate benefits sufficient to make adjuvant sorafenib worthwhile, and expected mild to moderate impairment of their HRQOL. Doctors judged moderate benefits sufficient, and larger benefits than their patients. Preferences varied over a wide range and had no consistent predictors. Results The median benefit judged sufficient by patients to make 1 year of sorafenib worthwhile was 9 months beyond 5 years, 1 year beyond 15 years, 5% beyond 65%, and 3% beyond 85%; and, for 3 years of sorafenib was 1 year beyond both 5 years and 15 years. Preferences varied across the entire possible range from an extra 1 month to 15 years and an extra 1% to 35%. Patients’ preferences were not strongly associated with their demographics or expectations about quality of life during treatment. The median benefit judged sufficient by doctors was 9 months beyond 5 years and 1 year beyond 15 years and 5% beyond 65% and 85%. Compared to patients, doctors’ judged larger benefits necessary for baseline prognoses of 15 years, 65% and 85% (p<0.04 for all). Methods Preferences were elicited by a self-administered questionnaire which used the time trade-off method to determine the minimum survival benefits judged sufficient to make adjuvant sorafenib worthwhile in 6 hypothetical scenarios. Baseline survival times were 5 and 15 years and baseline survival rates (at 5 years) were 50% and 65%. Four scenarios compared 1 year of sorafenib with no adjuvant treatment and two scenarios compared 3 years of sorafenib to 1 year of sorafenib. All tests were two-sided and non-parametric. Baseline responses of 180 patients (before sorafenib or placebo) and 96 of their doctors are reported. Acknowledgements PAS in SORCE is an ANZUP Cancer Trials Group Ltd study coordinated by the NHMRC Clinical Trials Centre at the University of Sydney, and partially supported by Medical Research Council, United Kingdom and Bayer Australia. Aim Benefit of adjuvant treatment is a gamble with patients either benefiting, relapsing despite treatment or not benefiting (cured by surgery). The aim of this study is to determine: 1. The minimum survival benefits patients and their doctors judge sufficient to make adjuvant sorafenib worthwhile, and 2. the factors influencing these preferences. References P Blinman et al; Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol 23(5):1104-10, 2012 Shomik Sengupta 1,4, Prunella Blinman 2,4, Andrew Martin 3,4, Jennifer Thompson 3,4, Trevor France 3,4, Ian Davis 1,4,5, Martin Stockler 2,3,4,6 1 Austin Health, Melbourne, VIC; 2 Concord Cancer Centre, NSW; 3 NHMRC Clinical Trials Centre, University of Sydney, NSW; 4 ANZUP Cancer Trials Group Ltd, NSW; 5 Monash University and Eastern Health, VIC; 6 Royal Prince Alfred Hospital, NSW No. 179 Posters Proudly Supported by: Most patients had a technical college or university education (59%), worked full-time (62%) and were married (80%). Fewer had dependent children (37%).
Your consent to our cookies if you continue to use this website.